Chugai Venture Fund
VC Fund
Boston, United States
Chugai Venture Fund is a pioneering investment firm that promotes innovation and creates revolutionary improvements in the life sciences industry.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Chugai Venture Fund invests in
Stages Chugai Venture Fund invests in
Countries Chugai Venture Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 3 (43%)
- Medical 2 (29%)
- SaaS 1 (14%)
- Health Care 1 (14%)
- Therapeutics 1 (14%)
Stage
- Series A 3 (43%)
- Venture - Series Unknown 2 (29%)
- Debt Financing 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
John Gustofson
Founder & President
|
Founder & President | Total investments: 10 | Find email | |
|
Mike Dial
Managing Director
|
Managing Director | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. | Venture - Series Unknown / Feb 19, 2026 | |
|
|
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. | Venture - Series Unknown / Feb 19, 2026 | |
|
|
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders and other conditions. With a growing collection of innovative cell surface proximity engagers and our in-house DualScreen™ discovery engine, our pipeline | $65M / Series A / Sep 16, 2025 | |
|
|
Leal Therapeutics develops novel therapeutics for patients. | $30M / Series A / Aug 27, 2025 | |
|
|
Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders. The company is based in Cambridge, Massachusetts. | $85M / Series A / May 12, 2025 | |
|
|
Leal Therapeutics develops novel therapeutics for patients. | Debt Financing / Oct 30, 2024 | |
|
|
Leal Therapeutics develops novel therapeutics for patients. | $6M / Venture - Series Unknown / Oct 30, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chugai Venture Fund invest in?
Chugai Venture Fund invests primarily in Biotechnology, Medical and SaaS startups, most often at Series A and Venture - Series Unknown stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Chugai Venture Fund?
Public channels for Chugai Venture Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Chugai Venture Fund?
The team at Chugai Venture Fund includes John Gustofson (Founder & President) and Mike Dial (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!